BioInvent: phase IIa study misses primary endpoint

Topline results of phase IIa study GLACIER with its lead product candidate monoclonal antibody BI-204 in patients with stable atherosclerotic vascular disease (atherosclerosis) failed to show statistically significant improvement in the primary endpoint relative change in inflammatory activity in an index arterial vessel. This will be reflected on the share of Bioinvent International (STO: BINV) today. The compound is partnered with Genentech, now a member of Roche Group which has acquired U.S. rights, while Bioinvent retains ex-U.S ownership. No drug-related safety issues were observed. The parties will further analyze the safety and efficacy data before a decision on the future of the compound is made.